- Home
- ESAB vs LEGN Comparison
ESAB vs LEGN Comparison
Compare ESAB & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | LEGN |
|---|---|---|
| Founded | 1904 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ESAB | LEGN |
|---|---|---|
| Price | $115.77 | $22.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $142.33 | $69.67 |
| AVG Volume (30 Days) | 524.5K | ★ 2.5M |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.95 | N/A |
| Revenue | ★ $2,792,325,000.00 | $909,045,000.00 |
| Revenue This Year | $3.25 | $68.83 |
| Revenue Next Year | $8.37 | $51.27 |
| P/E Ratio | $29.31 | ★ N/A |
| Revenue Growth | 1.19 | ★ 74.75 |
| 52 Week Low | $100.17 | $22.28 |
| 52 Week High | $135.84 | $45.30 |
Technical Indicators
Market Signals| Indicator | ESAB | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.82 | 21.96 |
| Support Level | $107.17 | $26.43 |
| Resistance Level | $114.52 | $28.97 |
| Average True Range (ATR) | 3.28 | 1.57 |
| MACD | 0.93 | -0.43 |
| Stochastic Oscillator | 87.03 | 0.91 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.